Literature DB >> 19449140

Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors.

Magdalena Slosar1, Poonam Vohra, Manju Prasad, Andrew Fischer, Robert Quinlan, Ashraf Khan.   

Abstract

Insulin-like growth factor mRNA binding protein 3 (IMP3) is an mRNA-binding protein that regulates transcription of insulin-like growth factor II affecting cell proliferation during embryogenesis. It is highly expressed in carcinomas of the pancreas, stomach, colon, rectum, kidneys, uterine cervix, lung, and ovary. The purpose of our study was to evaluate IMP3 expression in thyroid follicular lesions, to determine whether it has a role in differentiating among these lesions, and to understand their biological relationships. We immunostained 219 thyroid lesions selected from our surgical pathology archives including 14 hyperplastic colloid nodules (CN), 19 Hashimoto's thyroiditis (HT), two Graves disease (GD), ten Hürthle cell adenoma (HCA), 20 follicular adenoma (FA), 37 conventional papillary thyroid carcinoma (PTC), 60 follicular variant of papillary carcinoma (FVPC), 19 Hürthle cell carcinoma (HCC), 32 follicular carcinoma (FC), and six poorly differentiated/anaplastic carcinoma. Immunohistochemistry was performed on formalin-fixed sections using monoclonal antibody to IMP3. Clinicopathological data were also reviewed. In all cases, residual thyroid tissue, CN, HT, GD, HCA, and FA were completely negative for IMP3 staining. Of the 60 FVPC, 23 tumors (38%) were positive for IMP3, with 13 of these (22%) showing very strong staining (3+). Of the 32 FC, 22 tumors (69%) were positive, with seven (22%) showing very strong staining (3+). Furthermore, 33 out of 37 cases (89%) of PTC were negative for IMP3. In all four PTC cases that did stain positive, staining was weak-moderate (1-2+). Similarly, 15 out of 19 cases (79%) of HCC were negative. No significant correlation was found between pathologic tumor characteristics and IMP3 expression in differentiated follicular pattern thyroid carcinoma. With 100% specificity and 69% sensitivity for FC as compared to FA and 100% specificity for FVPC, again compared to FA, IMP3 has the potential to be diagnostically useful in differentiating malignant and benign follicular pattern thyroid lesions. This study also points to a possible common biological relationship between FC and FVPC that requires further investigation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19449140     DOI: 10.1007/s12022-009-9079-x

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  37 in total

1.  Immunohistochemical diagnosis of papillary thyroid carcinoma.

Authors:  C C Cheung; S Ezzat; J L Freeman; I B Rosen; S L Asa
Journal:  Mod Pathol       Date:  2001-04       Impact factor: 7.842

2.  Adenomas and follicular carcinomas of the thyroid display two major patterns of chromosomal changes.

Authors:  Patrícia Castro; Mette Eknaes; Manuel R Teixeira; Håvard E Danielsen; Paula Soares; Ragnhild A Lothe; Manuel Sobrinho-Simões
Journal:  J Pathol       Date:  2005-07       Impact factor: 7.996

3.  Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application.

Authors:  E Saggiorato; R De Pompa; M Volante; S Cappia; F Arecco; A P Dei Tos; F Orlandi; M Papotti
Journal:  Endocr Relat Cancer       Date:  2005-06       Impact factor: 5.678

Review 4.  Growth regulation of thyroid and thyroid tumors in humans.

Authors:  P E Goretzki; D Simon; C Dotzenrath; K M Schulte; H D Röher
Journal:  World J Surg       Date:  2000-08       Impact factor: 3.352

5.  The role of cell cycle regulatory proteins, cyclin D1, cyclin E, and p27 in thyroid carcinogenesis.

Authors:  S Wang; J Wuu; L Savas; N Patwardhan; A Khan
Journal:  Hum Pathol       Date:  1998-11       Impact factor: 3.466

6.  Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations.

Authors:  Zhaowen Zhu; Manoj Gandhi; Marina N Nikiforova; Andrew H Fischer; Yuri E Nikiforov
Journal:  Am J Clin Pathol       Date:  2003-07       Impact factor: 2.493

7.  Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.

Authors:  Krisztina Z Hanley; Michael S Facik; Patricia A Bourne; Qi Yang; Betsy O Spaulding; Thomas A Bonfiglio; Haodong Xu
Journal:  Cancer       Date:  2008-02-25       Impact factor: 6.860

8.  The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.

Authors:  Wenxin Zheng; Xiaofang Yi; Oluwole Fadare; Sharon X Liang; Maritza Martel; Peter E Schwartz; Zhong Jiang
Journal:  Am J Surg Pathol       Date:  2008-02       Impact factor: 6.394

9.  Expression of eukaryotic translation initiation factors 4E and 2alpha correlates with the progression of thyroid carcinoma.

Authors:  S Wang; R V Lloyd; M J Hutzler; I B Rosenwald; M S Safran; N A Patwardhan; A Khan
Journal:  Thyroid       Date:  2001-12       Impact factor: 6.568

10.  High-molecular-weight cytokeratin and cytokeratin-19 in the diagnosis of thyroid tumors.

Authors:  S J Raphael; G McKeown-Eyssen; S L Asa
Journal:  Mod Pathol       Date:  1994-04       Impact factor: 7.842

View more
  10 in total

1.  Cytological detection of papillary thyroid carcinomas by nuclear membrane decoration with emerin staining.

Authors:  Sofia Asioli; Francesca Maletta; Donatella Pacchioni; Rosanna Lupo; Gianni Bussolati
Journal:  Virchows Arch       Date:  2010-05-26       Impact factor: 4.064

2.  Comparison of the clinicopathological behavior of the follicular variant of papillary thyroid carcinoma and classical papillary thyroid carcinoma: A systematic review and meta-analysis.

Authors:  Jing Yang; Yanping Gong; Shuping Yan; Qingquan Shi; Jingqiang Zhu; Zhihui Li; Qiang Chen; Rixiang Gong
Journal:  Mol Clin Oncol       Date:  2015-04-06

3.  Imp3 expression in benign and malignant thyroid tumors and hyperplastic nodules.

Authors:  Sezer Kulaçoğlu; Gamze Erkılınç
Journal:  Balkan Med J       Date:  2015-01-01       Impact factor: 2.021

4.  Analysis of IMP3 expression in normal and neoplastic human pituitary tissues.

Authors:  Alberto Righi; Shuya Zhang; Long Jin; Bernd W Scheithauer; Kalman Kovacs; Gabor Kovacs; Miklos I Goth; Marta Korbonits; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2010-03       Impact factor: 3.943

Review 5.  IGF Bioregulation System in Benign and Malignant Thyroid Nodular Disease: A Systematic Review.

Authors:  Apostolos Karagiannis; Eva Kassi; Antonios Chatzigeorgiou; Michael Koutsilieris
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

6.  Insulin-like growth factor II mRNA binding protein 3 (IMP3) is overexpressed in prostate cancer and correlates with higher Gleason scores.

Authors:  Kristian Ikenberg; Florian R Fritzsche; Ursina Zuerrer-Haerdi; Irina Hofmann; Thomas Hermanns; Helge Seifert; Michael Müntener; Maurizio Provenzano; Tullio Sulser; Silvia Behnke; Josefine Gerhardt; Ashkan Mortezavi; Peter Wild; Ferdinand Hofstädter; Maximilian Burger; Holger Moch; Glen Kristiansen
Journal:  BMC Cancer       Date:  2010-06-30       Impact factor: 4.430

7.  Insulin growth factor-2 binding protein 3 (IGF2BP3) is a glioblastoma-specific marker that activates phosphatidylinositol 3-kinase/mitogen-activated protein kinase (PI3K/MAPK) pathways by modulating IGF-2.

Authors:  Ramaswamy Suvasini; Bhargava Shruti; Balaram Thota; Sridevi Vijay Shinde; Dinorah Friedmann-Morvinski; Zahid Nawaz; Krishnarao Venkatesh Prasanna; Kandavel Thennarasu; Alangar Sathyaranjandas Hegde; Arimappamagan Arivazhagan; Bangalore Ashwathnarayanarao Chandramouli; Vani Santosh; Kumaravel Somasundaram
Journal:  J Biol Chem       Date:  2011-05-25       Impact factor: 5.157

8.  A Concise Atlas of Thyroid Cancer Next-Generation Sequencing Panel ThyroSeq v.2.

Authors:  Jorge Alsina; Raul Alsina; Seza Gulec
Journal:  Mol Imaging Radionucl Ther       Date:  2017-02-09

Review 9.  Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression?

Authors:  Jessica L Bell; Kristin Wächter; Britta Mühleck; Nikolaos Pazaitis; Marcel Köhn; Marcell Lederer; Stefan Hüttelmaier
Journal:  Cell Mol Life Sci       Date:  2012-10-16       Impact factor: 9.261

10.  IMP3 overexpression occurs in various important cancer types and is linked to aggressive tumor features: A tissue microarray study on 8,877 human cancers and normal tissues.

Authors:  Christoph Burdelski; Nilofar Jakani-Karimi; Frank Jacobsen; Christina Möller-Koop; Sarah Minner; Ronald Simon; Guido Sauter; Stefan Steurer; Till S Clauditz; Waldemar Wilczak
Journal:  Oncol Rep       Date:  2017-11-02       Impact factor: 3.906

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.